慢性肝病中的抗凝治疗
Anticoagulation in chronic liver disease.
PubMed 文献 · J Hepatol · 2017-01-12
本文以大查房形式报告一例失代偿期肝病患者后续发生致死性肺栓塞的病例,讨论慢性肝病患者血栓性疾病负担,分析抗凝治疗的现有证据、安全性数据与临床困境,并探讨该领域的未来方向。
要点
- 失代偿期肝病患者可发生致死性肺栓塞,预防性抗凝或可避免静脉血栓栓塞症。
- 慢性肝病患者血栓性疾病负担较重,抗凝治疗需权衡出血与血栓风险。
- 慢性肝病抗凝的现有证据、安全性数据与临床困境仍是讨论重点。
核心结论
- 本文通过一例失代偿期肝病后发生致死性肺栓塞的病例,引出慢性肝病抗凝治疗中证据、安全性与临床困境的讨论。
研究设计与样本
- 本文为大查房(Grand Round)形式的病例报告与综述,描述一例失代偿期肝病男性患者的病例并汇总相关证据。
主要发现
- 该例失代偿期肝病患者后续发生致死性肺栓塞,若已给予预防性抗凝以预防静脉血栓栓塞症,该事件或许不会发生。
- 文中讨论了慢性肝病患者中血栓性疾病的负担,并分析抗凝治疗的现有证据、安全性数据与临床困境。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this Grand Round presentation, the case of a man with decompensated liver disease is described. He subsequently developed a fatal pulmonary embolism, which may not have occurred if he had been prescribed prophylactic anticoagulation to prevent venous thromboembolic disease. The burden of thrombotic disease in those with chronic liver disease is discussed, before a more detailed analysis of the current evidence, safety data, and clinical dilemmas regarding the use of anticoagulation in patients with chronic liver disease. Finally, the future directions within this field are explored.
来源:J Hepatol,查看原文。版权归原作者所有。
引用
- Dhar A, Mullish BH, Thursz MR, et al. Anticoagulation in chronic liver disease. J Hepatol. 2017. PMID: 28088580. doi:10.1016/j.jhep.2017.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。